Finding a Place for Tumor-specific T Cells in Targeted Cancer Therapy
Open Access
- 20 December 2004
- journal article
- review article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 200 (12) , 1533-1537
- https://doi.org/10.1084/jem.20042004
Abstract
A goal in cancer therapeutics is to develop targeted modalities that distinguish malignant from normal cells. T cells can discriminate diseased cells based on subtle alterations in peptides displayed in association with MHC molecules at the cell surface. Recent success using the adoptive transfer of tumor-specific T cells has fueled optimism that this approach may find a place as a targeted therapy for some human cancers.Keywords
This publication has 32 references indexed in Scilit:
- Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapyBlood, 2005
- Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's DiseaseThe Journal of Experimental Medicine, 2004
- CD8 T Cell Recognition of Endogenously Expressed Epstein-Barr Virus Nuclear Antigen 1The Journal of Experimental Medicine, 2004
- Cellular Immunotherapy for Follicular Lymphoma Using Genetically Modified CD20-Specific CD8+ Cytotoxic T LymphocytesMolecular Therapy, 2004
- Evidence for the Presentation of Major Histocompatibility Complex Class I–restricted Epstein-Barr Virus Nuclear Antigen 1 Peptides to CD8+ T LymphocytesThe Journal of Experimental Medicine, 2004
- Self-Inhibition of Synthesis and Antigen Presentation by Epstein-Barr Virus-Encoded EBNA1Science, 2003
- Adoptive-cell-transfer therapy for the treatment of patients with cancerNature Reviews Cancer, 2003
- Natural selection of tumor variants in the generation of “tumor escape” phenotypesNature Immunology, 2002
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002
- Epitope-specific Evolution of Human CD8+ T Cell Responses from Primary to Persistent Phases of Epstein-Barr Virus InfectionThe Journal of Experimental Medicine, 2002